新型化疗止吐药神经激肽-1受体拮抗剂的研究进展

发布时间：2019-02-14 17:57

【摘要】：本文对神经激肽-1受体拮抗剂药动学、药效学、临床研究、安全性等方面的研究进展进行综述。归纳和整理近几年有关神经激肽-1受体拮抗剂的文献报道和临床研究数据。神经激肽-1受体拮抗剂通过与神经激肽-1受体高选择性、强亲和力的结合,拮抗P物质的致吐作用,有效降低化疗相关恶心呕吐的发生,与5-羟色胺3受体拮抗剂和地塞米松联用相比于后两者联用可有效提高化疗患者的完全缓解率(P0.05),尤其在延迟期疗效显著(P0.05),且具有很好的安全性以及成本-效果优势。除此之外,对术后相关的恶心呕吐、瘙痒、肿瘤等的治疗也具有很好的疗效。神经激肽-1受体拮抗剂是防治化疗相关恶心呕吐的新突破,前景广阔,但临床还应对该类药物进行更深入的研究。
[Abstract]:This article reviews the pharmacokinetics, pharmacodynamics, clinical research and safety of neurokinin-1 receptor antagonists. The literature and clinical data of neurokinin-1 receptor antagonists were summarized and summarized in recent years. Neurokinin-1 receptor antagonist can effectively reduce the occurrence of chemotherapy-associated nausea and vomiting by combining with neurokinin-1 receptor with high selectivity and strong affinity. In combination with serotonin 3 receptor antagonist and dexamethasone, the complete remission rate of chemotherapy patients was significantly increased (P0.05), especially in the delayed period (P0.05). And has the very good security and the cost-effect superiority. In addition, the treatment of postoperative nausea and vomiting, itching, tumor and so on also has the very good curative effect. Neurokinin-1 receptor antagonist is a new breakthrough in the prevention and treatment of chemotherapy-related nausea and vomiting.
【作者单位】：北京大学医学部药学院药事管理与临床药学系;北京医院药学部;
【分类号】：R979.1

【共引文献】